Related content

A Comparison of Polychemotherapy and Melphalan/Prednisone for Primary Remission Induction, and Interferon-alpha for Maintenance Treatment, in Multiple Myeloma. A Prospective Trial of the German Myeloma Treatment Group

By Peest D.   Deicher H.   Coldewey R.   Leo R.   Bartl R.   Bartels H.   Braun H.J.   Fett W.   Fischer J.T.   Gobel B.   Harms P.   Henke R.   Hoffmann L.   Kreuser E.D.   Maier W.D.   Meier C.R.   Oertel J.   Petit M.   Planker M.   Platzeck C.   Respondek M.   Schafer E.   Schumacher K.   Stennes M.   Stenzinger W.   Tirier C.   Wagner H.   Weh H.J.   von Wussow P.   Wysk J.  

European Journal of Cancer, Vol. 31, Iss. 2, 1995-01 ,pp. : 146-151

Elsevier

Access to resources Recommend Favorite

Should alpha-interferon be included as standard treatment in multiple myeloma?

By Zulian G.B.  

European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. : 18-22

Elsevier

Access to resources Recommend Favorite

Should alpha-interferon be included as standard treatment in multiple myeloma?

By Browman G.P.  

European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. : 22-24

Elsevier

Access to resources Recommend Favorite

Should alpha-interferon be included as standard treatment in multiple myeloma?

By Ludwig H.   Fritz E.  

European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. : 12-17

Elsevier

Access to resources Recommend Favorite

Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma

By Chiou Tzeon-Jye   Wang Teng-Hsu   Chao Tsu-Yi   Lin Sheng-Fung   Tang Jih-Luh   Chen Tsai-Yun   Chang Ming-Chih   Hsueh Erh-Jung   Chen Po-Min  

Cancer Investigation, Vol. 25, Iss. 3, 2007-04 ,pp. : 140-147

Informa Healthcare

Access to resources Recommend Favorite